VANCOUVER, Aug. 15, 2019 – Cannara Biotech Inc. (“Cannara Biotech”) (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB), an emerging vertically integrated cannabis company focused on the cultivation and sale of dried premium cannabis and cannabis-infused products, today announced the appointment of Barry Laxer as Cannara’s new Chief Operating Officer, effective August 14, 2019. Barry is a successful business leader that brings over 25 years of experience of leading large-scale operations both domestically and internationally.
“We are excited to welcome Barry to the leadership team, knowing his contributions will help accelerate our company to its next stage of growth,” said Zohar Krivorot, President and CEO of Cannara.
Barry will replace Evan Morris, who has helped bring the construction phase of our Farnham facility to completion. “We would like to thank Evan for his many contributions to Cannara over the past year and wish him all the best in his future endeavours,” said Mr. Krivorot.
About Cannara Biotech
Cannara Biotech (CSE: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is building one of the largest indoor cannabis cultivation facilities (625,000 square feet) in Canada and the largest in Quebec. Leveraging Quebec’s low electricity costs, Cannara Biotech’s facility will produce premium-grade indoor cannabis and cannabis-infused products for the Canadian and international markets.
The CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding “Forward-Looking” Information
This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Cannara Biotech Inc.